Neoplasms, Nerve Tissue clinical trials at UC Health
1 research study open to eligible people

• Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

  open to eligible people ages 1 month and up

  This is a Phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients age ≥ 1 month and older with NTRK fusion cancers treated with a prior TRK inhibitor.

  at UCLA UCSD

Last updated: June 4, 2019